Emerging treatments in Castleman disease – a critical appraisal of siltuximab
Jean L Koff, Sagar Lonial Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA Abstract: Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/96ec89b0400a4c8dad3c61409a5a9c31 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:96ec89b0400a4c8dad3c61409a5a9c31 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:96ec89b0400a4c8dad3c61409a5a9c312021-12-02T04:48:22ZEmerging treatments in Castleman disease – a critical appraisal of siltuximab1177-5491https://doaj.org/article/96ec89b0400a4c8dad3c61409a5a9c312016-01-01T00:00:00Zhttps://www.dovepress.com/emerging-treatments-in-castleman-disease-ndash-a-critical-appraisal-of-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Jean L Koff, Sagar Lonial Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA Abstract: Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine. Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a disease lacking efficacious therapy. Here, we review the findings of recent studies evaluating single-agent siltuximab treatment in CD, including the first-ever randomized clinical trial in this disease. Although much more work is needed to establish a standardized treatment approach, siltuximab appears to be a safe and effective treatment for patients with newly diagnosed and previously treated CD. Keywords: treatment, lymphoma, interleukin-6Koff JLLonial SDove Medical PressarticleCastlemans diseasesiltuximabMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2016, Iss Issue 1, Pp 9-15 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Castlemans disease siltuximab Medicine (General) R5-920 |
| spellingShingle |
Castlemans disease siltuximab Medicine (General) R5-920 Koff JL Lonial S Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| description |
Jean L Koff, Sagar Lonial Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA Abstract: Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine. Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a disease lacking efficacious therapy. Here, we review the findings of recent studies evaluating single-agent siltuximab treatment in CD, including the first-ever randomized clinical trial in this disease. Although much more work is needed to establish a standardized treatment approach, siltuximab appears to be a safe and effective treatment for patients with newly diagnosed and previously treated CD. Keywords: treatment, lymphoma, interleukin-6 |
| format |
article |
| author |
Koff JL Lonial S |
| author_facet |
Koff JL Lonial S |
| author_sort |
Koff JL |
| title |
Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| title_short |
Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| title_full |
Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| title_fullStr |
Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| title_full_unstemmed |
Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| title_sort |
emerging treatments in castleman disease – a critical appraisal of siltuximab |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://doaj.org/article/96ec89b0400a4c8dad3c61409a5a9c31 |
| work_keys_str_mv |
AT koffjl emergingtreatmentsincastlemandiseasendashacriticalappraisalofsiltuximab AT lonials emergingtreatmentsincastlemandiseasendashacriticalappraisalofsiltuximab |
| _version_ |
1718401024087031808 |